rs397507906
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000059.4(BRCA2):c.7234_7235insG(p.Thr2412SerfsTer2) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000059.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.7234_7235insG | p.Thr2412SerfsTer2 | frameshift_variant | Exon 14 of 27 | 5 | NM_000059.4 | ENSP00000369497.3 | ||
BRCA2 | ENST00000530893.7 | c.6865_6866insG | p.Thr2289SerfsTer2 | frameshift_variant | Exon 14 of 27 | 1 | ENSP00000499438.2 | |||
BRCA2 | ENST00000614259.2 | n.7234_7235insG | non_coding_transcript_exon_variant | Exon 13 of 26 | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Observed in individuals with breast and/or ovarian cancer (Esteban Cardenosa et al., 2010; Tazzite et al., 2012; de Juan Jimenez et al., 2013; de Juan et al., 2015; Jouali et al., 2016; Elalaoui et l., 2022); Also known as 7462_7463insG or 7462insG; This variant is associated with the following publications: (PMID: 26026974, 27129401, 24019637, 23479189, 20033483, 27446417, 24606420, 25780794, 24312913, 34242281, 28779219, 32341426, 32885271, 32778078, 35578052, 35216584, 35858847, 31060517, 22425665) -
This sequence change inserts 1 nucleotide in exon 14 of the BRCA2 mRNA (c.7234_7235insG), causing a frameshift at codon 2412. This creates a premature translational stop signal 2 amino acid residues later (p.(Thr2412Serfs*2) and is expected to result in an absent or disrupted protein product. This variant has been described in the literature in an individual with breast and ovarian cancer (PMID: 20711702, 22425665, 23479189, 26026974, 27446417). Also, this variant has been defined as c.7462_7463insG, c.7234insG, c.7235insG, c.7462insG, or 7463insG in the literature. The mutation database ClinVar contains entries for this variant (Variation ID: 52295). -
This frameshift variant causes the premature termination of BRCA2 protein synthesis. In addition, it has been reported in individuals with breast cancer in the published literature (PMID: 32885271 (2021) and 23479189 (2013)). Based on the available information, this variant is classified as pathogenic. -
Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:2
Variant allele predicted to encode a truncated non-functional protein. -
- -
Malignant tumor of breast Pathogenic:1
The BRCA2 p.Thr2412Serfs*2 variant was identified in 5 of 22780 proband chromosomes (frequency: 0.0002) from Moroccan and European individuals or families with breast/ovarian cancer (Tazzite 2012, Rebbeck 2018). The variant was also identified in dbSNP (ID: rs397507906) “With Pathogenic allele”, ClinVar (classified pathogenic, reviewed by an expert panel (2016); submitters: ENIGMA, CIMBA, GeneDx and GeneKor MSA), and LOVD 3.0. The variant was not identified in UMD-LSDB. The variant was not identified in the following control databases: the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The c.7234_7235insG variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 2412 and leads to a premature stop codon at position 2413. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the BRCA2 gene are an established mechanism of disease in hereditary breast and ovarian cancer and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. -
Hereditary breast ovarian cancer syndrome Pathogenic:1
This sequence change creates a premature translational stop signal (p.Thr2412Serfs*2) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with a personal and family history of breast cancer (PMID: 22425665, 23479189, 28779219). This variant is also known as c.7235insG. ClinVar contains an entry for this variant (Variation ID: 52295). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at